Aspreva Pharmaceuticals
Aspreva Pharmaceuticals reports on new developments
Published in Lab Law Weekly, August 24th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Aspreva Pharmaceuticals.
Report 1: Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) and Roche today released preliminary results for a clinical trial comparing CellCept (oral mycophenolate mofetil, MMF) to intravenous cyclophosphamide (IVC), which is the current standard of care, for inducing treatment response in the induction phase of patients suffering from lupus nephritis.
Although response rates were similar in both arms, the trial did not meet its primary...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
Source: Lab Law Weekly (2007-08-24)
More Articles from Lab Law Weekly
- Aarp
Seniors Set to be Hit Hard by Illinois Budget - Americans United for Life
Kansas Abortionist Tiller's Claims Without Merit Americans United for Life Amicus Brief Says - BG Medicine, Inc.
BG Medicine Files US Registration Statement with SEC in Support of Euronext Amsterdam IPO - Bioengineering
AutoImmune Inc. Reports 2007 Second Quarter Financial Results - Bioengineering
Point Therapeutics Reports Second Quarter 2007 Financial Results - Biomedicine
Spectral reports second quarter results - More from this issue of Lab Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
